Abstract 1165
Background
Although several studies report the clinical characteristics of bacteremia by Aeromonas species, there is a lack of studies about the bacteremia course in hematologic malignancies. Our aim was to determine the risk factors for bacteremia-associated mortality by Aeromonas sobria in patients with hematological malignancies.
Methods
We performed a retrospective cohort study, by reviewing 37 medical records of patients treated at the “Instituto Nacional de Enfermedades Neoplasicas-Peru”, in the period of 2000-2017. We considered a bacteremia-related death if it occurred within the first 7 days of A. sobria isolation, or during the acute course of sepsis. Risk factors were assessed by the Multivariate Cox regression analysis at 30 days after the patient’s admission.
Results
The median age was 24y (2-74y), six patients (16.2%) had ≥65y, and 54.1% were male. The most common diagnosis was lymphoid leukemia (51.4%), followed by myeloid leukemia (27%), high-grade lymphoma (18.9%), and multiple myeloma (2.7%); and 37.8% had community-acquired bacteremia. The gastrointestinal system was the most common primary source of infection (62.2%), followed by the osteoarticular system (18.9%). The mortality rate was 27%, and 11 cases (29.7%) presented septic shock. Furthermore, antibiotic use was as follow, meropenem (64.9%), ceftazidime (37.8%), and amikacin (29.7%). Multivariate Cox regression identified age ≥65, shock, and no disease remission as independent risk factors for mortality (Table). Risk factors for Bacteremia-Associated Mortality of Aeromona sobria.Table: 1093P
Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|
HR | 95% CI | P-value | HR | 95% CI | P-value | |
Age ≥65 | 5.48 | 1.5-19.7 | 0.01 | 8.13 | 1.7-39.4 | 0.009 |
Community-acquire bacteremia | 9.73 | 2.1– 46.1 | 0.004 | - | - | - |
Shock | 13.21 | 2.8–63.0 | 0.001 | 7.06 | 1.5-34.4 | 0.016 |
Non-disease remission | 14.31 | 1.8–113.3 | 0.012 | 10.46 | 1.2-89.8 | 0.024 |
Conclusions
Patients with hematological malignancy infected by A. sobria that either is ≥ 65-years-old does not have a disease remission or develop shock, the risk of dying increases. The physicians can use our results to guide the prognosis of patients infected by this bacteria.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
860 - Dose differential modulation of the autophagic behavior of estrogen expressing breast carcinoma cells
Presenter: Mariam Fouad
Session: Poster Display session 1
Resources:
Abstract
2304 - Synthetic peptide of tumor–associated antigen L6 formulated with polymer-based adjuvant enhances anti-tumor effects in mice
Presenter: Shih-jen Liu
Session: Poster Display session 1
Resources:
Abstract
4419 - Improving detection level of somatic mosaicism in neurofibromatosis type 1
Presenter: Kristina Karandasheva
Session: Poster Display session 1
Resources:
Abstract
5283 - Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship of ABN401, a highly selective Met inhibitor, in gastric and non-small-cell lung cancer models
Presenter: JooSeok Kim
Session: Poster Display session 1
Resources:
Abstract
5488 - Transcription factors of Snail family in the regulation of resistance of breast cancer cells to hypoxic conditions
Presenter: Alvina Khamidullina
Session: Poster Display session 1
Resources:
Abstract
5417 - Metastasis is impaired by endothelial-specific Dll4 loss-of-function through inhibition of epithelial-to-mesenchymal transition and reduction of cancer stem cells and circulating tumour cells
Presenter: Liliana Mendonça
Session: Poster Display session 1
Resources:
Abstract
5494 - Identification of novel and known FGFR gene fusions in Chinese non-small cell lung cancer
Presenter: Weixin Zhao
Session: Poster Display session 1
Resources:
Abstract
3412 - WNT pathway mutations (APC/CTNNB1) and immune checkpoint inhibitors (ICI) response in metastatic non-small cell lung cancer (NSCLC) patients.
Presenter: Francisco Javier Ros Montana
Session: Poster Display session 1
Resources:
Abstract
1815 - Leukocytosis as a negative prognostic factor in patients with lung cancer: Which subpopulation of leukocytes is responsible?
Presenter: Filip Kohutek
Session: Poster Display session 1
Resources:
Abstract
5022 - Identification of MET gene amplifications using next-generation sequencing in non-small cell lung cancer patients
Presenter: Sergi Clavé
Session: Poster Display session 1
Resources:
Abstract